Statin Intake Is Associated With Decreased Insulin Sensitivity During Cardiac Surgery

HIROAKI SATO, MD, PHD1
GEORGE CARVALHO, MD, MSC1
TAMAKI SATO, MD1
ROUPEN HATZAKORZIAN, MD1
RALPH LATTERMANN, MD, PHD1
TAKUMI CODEGE-MARUYAMA, MD1
TAKASHI MATSUKAWA, MD, PHD1
THOMAS SCHRICKER, MD, PHD1

OBJECTIVE—Surgical trauma impairs intraoperative insulin sensitivity and is associated with postoperative adverse events. Recently, preprocedural statin therapy is recommended for patients with coronary artery disease. However, statin therapy is reported to increase insulin resistance and the risk of new-onset diabetes. Thus, we investigated the association between preoperative statin therapy and intraoperative insulin sensitivity in nondiabetic, dyslipidemic patients undergoing coronary artery bypass grafting.

RESEARCH DESIGN AND METHODS—In this prospective, nonrandomized trial, patients taking lipophilic statins were assigned to the statin group and hypercholesterolemic patients not receiving any statins were allocated to the control group. Insulin sensitivity was assessed by the hyperinsulinemic-normoglycemic clamp technique during surgery. The mean, SD of blood glucose, and the coefficient of variation (CV) after surgery were calculated for each patient. The association between statin use and intraoperative insulin sensitivity was tested by multiple regression analysis.

RESULTS—We studied 120 patients. In both groups, insulin sensitivity gradually decreased during surgery with values being on average ~20% lower in the statin than in the control group. In the statin group, the mean blood glucose in the intensive care unit was higher than in the control group (153 ± 20 vs. 140 ± 20 mg/dL; P < 0.001). The oscillation of blood glucose was larger in the statin group (SD, P < 0.001; CV, P = 0.001). Multiple regression analysis showed that statin use was independently associated with decreased intraoperative insulin sensitivity (B = −0.16; P = 0.03).

CONCLUSIONS—Preoperative use of lipophilic statins is associated with increased insulin resistance during cardiac surgery in nondiabetic, dyslipidemic patients.

Diabetes Care 35:2095–2099, 2012

Hypercholesterolemia has long been recognized as a risk factor for atherosclerosis and coronary heart disease. As cholesterol-lowering agents such as hydroxymethylglutaryl CoA reductase inhibitors (statins) reduce cardiovascular morbidity (1), the American College of Cardiology/American Heart Association (ACC/AHA) recommends their use in patients with unstable angina or myocardial infarction (2). Further evidence suggests that patients undergoing surgical and nonsurgical coronary revascularization procedures can benefit from the anti-inflammatory properties of statins (3,4). Accumulated results showing a reduced incidence of ischemic events and arrhythmias in the presence of statin therapy (5,6) prompted the ACC/AHA to advocate for the administration of statins in coronary artery bypass grafting (CABG) (7) and in noncardiac surgery (8).

More recent studies indicate that statins increase the risk of new-onset diabetes (9–12). In particular, the use of atorvastatin has been shown to cause insulin resistance in hypercholesterolemic, nondiabetic patients (13). This metabolic effect of statin therapy is relevant for patients undergoing major surgery, who typically, as a result of stress-induced endocrine changes, develop hyperglycemia and insulin resistance, the so-called diabetes of the injury (14,15). On the basis of previous observations demonstrating a significant relationship between intraoperative insulin sensitivity and major complications after cardiac surgery (16,17), we investigated whether statin therapy is associated with decreased insulin sensitivity in nondiabetic, dyslipidemic patients undergoing CABG.

RESEARCH DESIGN AND METHODS

Patients and surgery

This study was conducted according to the Declaration of Helsinki. With approval from the McGill University Health Center Research Ethics Board, we included patients scheduled for elective CABG at the Royal Victoria Hospital (between October 2008 and March 2010) in this comparative, prospective, nonrandomized study. Patients were screened for inclusion and exclusion criteria and statin use. After obtaining written informed consent, patients taking lipophilic statins (atorvastatin or rosuvastatin) for at least 3 months were assigned to the statin group, whereas consenting, hypercholesterolemic patients not receiving any statins (LDL cholesterol >100 mg/dL) were allocated to the control group.

Patients scheduled for off-pump CABG, emergency procedures, or procedures with anticipated deep hypothermic circulatory arrest were excluded. We also excluded patients who were on hemodialysis or had troponin I levels ≥0.5 ng/L. Patients with a confirmed diagnosis of type 2 diabetes and receiving treatment (oral antihyperglycemic agents or insulin) were also excluded. Patients not known to have diabetes presenting with blood glucose levels >7.0 mmol/L (126 mg/dL) or glycated hemoglobin A1c (HbA1c) >6.0% were also not eligible.

Patients received standardized general anesthesia using sufentanil and midazolam supplemented with inhaled sevoflurane.

From the 1Department of Anesthesia, Royal Victoria Hospital, McGill University Health Center, Montreal, Quebec, Canada; and the 2Department of Anesthesiology, Yamanashi University, Yamanashi, Japan. Corresponding author: Hiroaki Sato, hssato@yamanashi.ac.jp. Received 19 November 2011 and accepted 27 April 2012. DOI: 10.2337/dc11-2251

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
During cardiopulmonary bypass (CPB), mean arterial pressure was maintained between 50 and 70 mmHg. Moderate hemodilution (hematocrit 20–25%) and mild hypothermia (34°C) were tolerated during CPB.

**Measurements**

Insulin sensitivity was assessed by the hyperinsulinemic-normoglycemic clamp technique, the gold standard to quantify insulin sensitivity in humans. Before induction of anesthesia, insulin (Humulin R; Eli Lilly and Company, Indianapolis, IN) was intravenously administered at 5 μU·kg⁻¹·min⁻¹. Approximately 10 min after starting the insulin infusion, and when the blood glucose was <6.1 mmol/L (110 mg/dL), 20% dextrose supplemented with phosphate (30 mmol/L) was administered. Arterial blood glucose concentrations were determined every 5 min, and the dextrose infusion was adjusted to maintain blood glucose at 5.0 mmol/L (90 mg/dL). The dextrose infusion rate during steady-state conditions, before, during, and toward the end of CPB, was used as an indicator of insulin sensitivity. We assumed steady-state conditions if the coefficient of variation (CV) of five subsequent dextrose infusion rates was <5%. Percentage changes in insulin sensitivity between baseline (after anesthesia induction before surgery) and the end of CPB were calculated in each group.

At the end of surgery (skin closure), the insulin infusion was stopped. The dextrose infusion was maintained for 2 h to avoid hypoglycemia. If the blood glucose was >8.0 mmol/L (144 mg/dL), an insulin infusion of 2 units/h was started in the intensive care unit (ICU). This was then titrated according to the following insulin sliding scale, aiming at a blood glucose between 4.0 and 8.0 mmol/L (72 and 144 mg/dL): if blood glucose <10.0 mmol/L (180 mg/dL), increase insulin infusion by 3 units/h; 8.0–10.0 mmol/L (144–180 mg/dL), increase insulin infusion by 2 units/h; 6.1–7.9 mmol/L (109–143 mg/dL), increase insulin infusion by 1 unit/h; 4.0–6.0 mmol/L (72–108 mg/dL), maintain current insulin infusion rate; <4.0 mmol/L (71 mg/dL), stop insulin infusion and administer 10 mL of 20% dextrose; or drops to a lower blood glucose range, maintain current insulin infusion rate.

Blood glucose was measured hourly, and the average blood glucose during the first 24 h after surgery was calculated. In each patient, the mean and SD of blood glucose concentration after surgery were calculated as arithmetical mean and SD of the entire set of measurements postoperatively. To evaluate relative variability, the CV (SD/average blood glucose) was also calculated for each patient.

**Statistics**

A previous study reported that insulin sensitivity decreased toward the end of CPB during cardiac surgery (16). In the present study, the primary outcome was lowest insulin sensitivity, i.e., insulin sensitivity at the end of CPB. The secondary outcome was blood glucose control in the ICU. Data are presented as means ± SD or number (percentage). Patient demographics were compared using Student t test or χ² test for categorical variables. Patient sensitivities at each time point, percentage changes of insulin sensitivity, mean blood glucose values, and SD and CV of blood glucose between the two groups were compared using Student t test. Insulin sensitivity was compared using two-way ANOVA with repeated measures across time and a comparison across groups. Multiple regression analysis was performed to determine factors related to intraoperative insulin sensitivity at the end of CPB. The variables used for the analysis were age, BMI, HbA1c, fasting blood glucose, homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, systolic blood pressure, use of ACE inhibitors, use of β-blockers, use of Ca-channel blockers, use of statins, and baseline level of insulin sensitivity. Two-sided P values <0.05 were considered statistically significant.

The sample size was calculated based on the result of a previous investigation showing a 10% increase in insulin resistance (HOMA-IR) by statin therapy (13). In order to achieve a power level of 90%, with an α error of 5%, 60 patients were required in each group. All statistical analyses were performed using SPSS 19 for Windows (IBM, Chicago, IL) and PASS 11 (NCSS, Kaysville, UT).

**RESULTS**—We enrolled 123 nondiabetic, dyslipidemic patients, 62 of whom were taking statins and 61 who were not taking statins. Once the statin group had 62 patients, we stopped assessing patients

---

**Figure 1**—Patient distribution. Patients (n = 369) were assessed for eligibility, and 123 patients were enrolled. After allocation, three patients were excluded, one for intra-aortic balloon pump (IABP) insertion before CPB and two for switched surgical procedure to off-pump CABG.
on statins for the study and then only approached hypercholesterolemic patients not on statins. After allocation, three patients were excluded, two for switched surgical procedures to off-pump CABG and one for requirement for intra-aortic balloon pump during surgery (Fig. 1).

Patient demographics were similar between groups except for total and LDL cholesterol, which were lower in the statin group (Table 1). Target glycemia was achieved in both groups during surgery (mean blood glucose, 5.1 ± 0.3 mmol/L [92 ± 5 mg/dL] in the statin group and 5.0 ± 0.4 mmol/L [90 ± 7 mg/dL] in the control group; \( P = 0.263 \)). The oscillation of blood glucose during surgery was also comparable (CV, 13.9 ± 3.4% in statin group and 13.7 ± 3.6% in control group; \( P = 0.765 \)).

There was no significant difference of the insulin sensitivity at the baseline point (\( P = 0.18 \)) (Table 2). In both groups, insulin sensitivity gradually decreased toward the end of CPB (\( P < 0.001 \)). The insulin sensitivities were lower in the statin group than in the control group (\( P < 0.001; CV, P = 0.001 \)) (Table 2). Multiple regression analysis showed that BMI, HDL cholesterol, triglycerides, baseline level of insulin sensitivity, and statin use were independently associated with the insulin sensitivity at the end of CPB (Table 3).

### CONCLUSIONS

The results of this prospective, nonrandomized study demonstrate increased insulin resistance during CABG in patients on statin therapy.

Statins are usually given to decrease plasma LDL concentrations and reduce the risk of ischemic heart disease and stroke (1,19). Although the clinical benefits of statins in nonsurgical patients have long been recognized, some evidence also supports their preemptive use in patients undergoing major surgery and cardiac surgery (20–24).

More recently, however, concerns have been raised about potential diabetogenic effects of statins, with potential relevance for surgical patients. Two meta-analyses including >100,000 participants concluded that long-term statin intake increases the risk of new-onset diabetes (9,25). In the JUPITER study (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), which enrolled 17,802 nondiabetic adults, rosuvastatin intake >1.9 years increased the incidence of diabetes by ~20% (26).

Several mechanisms may be responsible for these diabetogenic effects (27). Statins, particularly the lipophilic compounds, have been shown to inhibit glucose-induced cytosolic Ca\(^{2+}\) elevations and insulin secretion due to blockade of L-type Ca\(^{2+}\) channels in rat islet \( \beta \)-cells (28). In type 2 diabetic mice and human subjects treated for 3 months, atorvastatin impaired glucose tolerance and GLUT4 expression by inhibiting isoprenoid biosynthesis (29). High doses of lipophilic statins decreased insulin secretion from MIN6 \( \beta \)-cell lines, mediated either by the inhibition of hydroxymethylglutaryl CoA reductase or direct cytotoxicity (30). In hypercholesterolemic patients, atorvastatin therapy aggravated insulin resistance and elevated HbA1c levels, which may be the result of decreased plasma adiponectin concentrations (13). On the other hand, major surgical tissue trauma leads to stereotypical alterations in glucose metabolism, including stimulated glucose production and impaired glucose utilization. Much of this metabolic derangement can be explained by specific neuroendocrine changes, such as increased circulating concentrations of cortisol, glucagon, and catecholamines (14). These hormones affect glucose homeostasis by inhibiting insulin secretion and/or counteracting its peripheral action, causing impairment of tissue insulin sensitivity, the so-called diabetes of the injury (15,31). A previous study showed that intraoperative insulin sensitivity decreased toward the end of CPB in cardiac surgery (16). In the present study, preemptive lipophilic statin use together with surgical stress could work synergistically to worse intraoperative insulin sensitivity.

Insulin resistance is a typical feature of the endocrine response to surgery, leading to impaired glucose tolerance and hyperglycemia (15,31). Hyperglycemia has been shown to be an independent risk factor for death and cardiovascular, respiratory, infectious, and renal complications in nondiabetic and diabetic surgical patients (32–34). A link between the impairment of intraoperative insulin sensitivity and

### Table 1—Patient demographics

|                      | Control | Statin | \( P \) value |
|----------------------|---------|--------|-------------|
| Number (n)           | 60      | 60     |             |
| Age (years)          | 65 ± 12 | 64 ± 11| 0.74        |
| Weight (kg)          | 81 ± 17 | 83 ± 15| 0.42        |
| Height (m)           | 1.69 ± 0.10 | 1.72 ± 0.08 | 0.10 |
| BMI (kg/m\(^2\))     | 28.2 ± 5.3 | 28.0 ± 4.1 | 0.80 |
| Sex (male/female)    | 38 / 22 | 42 / 18| 0.44        |
| HbA1c (%)            | 5.4 ± 0.5 | 5.5 ± 0.4 | 0.23 |
| Fasting blood glucose (mmol/L) | 5.7 ± 0.6 | 5.9 ± 0.9 | 0.11 |
| HOMA-IR              | 2.4 ± 1.4 | 2.6 ± 1.5 | 0.59 |
| Total cholesterol (mg/dL) | 193 ± 40 | 149 ± 44* | <0.01 |
| HDL cholesterol (mg/dL) | 34 ± 11  | 35 ± 12  | 0.77 |
| Triglycerides (mg/dL) | 138 ± 68 | 139 ± 68 | 0.97 |
| LDL cholesterol (mg/dL) | 131 ± 32 | 88 ± 35* | <0.01 |
| Systolic blood pressure (mmHg) | 129 ± 23 | 134 ± 23 | 0.47 |
| Creatinine (\( \mu \)mol/L) | 94 ± 18  | 92 ± 19  | 0.43 |
| ACE inhibitors, n (%) | 26 (43) | 32 (53) | 0.27 |
| \( \beta \)-Blockers, n (%) | 42 (70) | 38 (63) | 0.44 |
| Ca-channel blockers, n (%) | 8 (13)  | 7 (12)  | 0.78 |
| Aortic cross-clamp time (min) | 81 ± 27 | 83 ± 24 | 0.70 |
| CPB time (min)       | 100 ± 32 | 106 ± 34 | 0.29 |
| Duration of surgery (min) | 209 ± 52 | 216 ± 51 | 0.49 |
| Lowest T (\(^{\circ}\)C) | 33.8 ± 1.1 | 33.9 ± 1.0 | 0.68 |

Data are mean ± SD or number (%). Creatinine, preoperative creatinine plasma concentration; T, core body temperature. *\( P < 0.05 \) vs. control.
Clinical outcomes were observed after elective cardiac surgery, indicating that insulin resistance during surgery, rather than the presence of diabetes per se, is a predictor of major complications, in particular infections (16). Independent of the patient’s diabetic state, a reduction of insulin sensitivity by 50% was associated with a five- to sixfold increased incidence of major complications, including 30-day mortality, myocardial failure, stroke, renal failure requiring dialysis, and serious infections (severe sepsis, pneumonia requiring endotracheal intubation, and deep sternal wound infection) (17). Our present finding demonstrating decreased intraoperative insulin sensitivity in the presence of statin therapy may therefore be relevant in the cardiac surgery patient population.

Increased insulin resistance by statin intake in the current study worsened glycemic control and resulted in a greater oscillation of blood glucose. There is evidence suggesting that the variability of blood glucose, rather than the absolute glycemic value, influences outcome (18). It has been proposed that fluctuations in glycemia trigger oxidative stress to a greater degree than sustained hyperglycemia (35). Data obtained in critical care showed that ICU survivors experienced less blood glucose variability than nonsurvivors (CV of glucose in survivors, 20 ± 12%; in nonsurvivors, 26 ± 13%) (18). In our study, the CV of postoperative blood glucose in the statin group was greater than in the control group and similar to the value observed in the previously reported nonsurvivor group of critically ill patients.

Supported by some evidence suggesting improved outcomes after cardiac surgery with statin intake (36), current guidelines of the European Society of Cardiology, the ACC, and the AHA recommend their use in patients undergoing CABG (7). These recommendations, however, are based on the results of small, randomized, controlled trials and observational studies and, thus, are inevitably subjected to the influence of potential confounders. The “healthy user effect” with statins has been associated with a reduction in adverse events. These patients who adhere to a medication schedule also engage in a healthy lifestyle and meet a primary care physician more often, which may secondarily result in better outcomes (37). It also must be emphasized that even if cardiovascular end points, i.e., atrial fibrillation and myocardial infarction, are reduced after cardiac surgery, poor glycemic control may have a negative impact on other relatively common, major, noncardiovascular complications, such as infections and renal morbidity. A large, prospective, randomized, controlled trial is needed to determine the clinical relevance of preoperative statin therapy in the cardiac surgery patient population for cardiac and noncardiac events.

We acknowledge several limitations of the study. Depending on their solubility, statins can be categorized as hydrophilic (pravastatin) or lipophilic (atorvastatin and rosuvastatin) (38). Whereas lipophilic statins, particularly when administered in high doses, have pleiotropic effects, such as impairment of insulin secretion and exacerbation of insulin resistance (28,39), hydrophilic statins lower plasma cholesterol to a lesser extent and may in fact reduce the frequency of diabetes, as shown for pravastatin in the West of Scotland Coronary Prevention Study (40). In the present protocol, only patients on lipophilic statins were eligible; therefore, our findings do not apply to patients taking hydrophilic compounds. The current study, although prospective, is not a randomized, double-blinded clinical trial nor is it designed or powered to assess patient outcomes. In conclusion, preoperative use of lipophilic statins is associated with increased insulin resistance during cardiac surgery in nondiabetic, dyslipidemic patients.

Acknowledgments—H.S. is supported by a grant from the Research Institute of Yamanashi University, Yamanashi, Japan. G.C. and R.L. are supported by grants from the Research Institute of the McGill University Health Center, Montreal, Quebec, Canada. R.L. is receiving a salary grant from the Fonds de la Recherche en Sante du Quebec, Montreal, Quebec, Canada. T.Sc. is supported by the Canadian Institutes of Health Research, Ottawa, Ontario, Canada.

No potential conflicts of interest relevant to this article were reported.

H.S. contributed to statistical analysis and data interpretation and drafted the manuscript. G.C. and R.L. researched data and contributed to discussion. T.Sa., R.H., and T.C.-M. contributed to data collection. T.M. contributed to statistical analysis. T.Sc. reviewed and edited the manuscript. T.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Ann Wright (Royal Victoria Hospital) for reviewing the manuscript.

References
1. Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056

Table 2—Outcomes

| Independent variable      | Control       | Statin        |
|---------------------------|---------------|---------------|
| Age (y)                   | 52 ± 1.8      | 49 ± 1.8      |
| BM1 (kg/m²)               | 1.6 ± 0.7     | 1.5 ± 0.7     |
| HbA1c (%)                 | 6.7 ± 1.3     | 6.4 ± 1.3     |
| Fasting blood glucose (mmol/L) | 5.2 ± 1.1   | 5.1 ± 1.1     |
| HOMA-IR                   | 0.5 ± 0.2     | 0.4 ± 0.2     |
| Total cholesterol (mg/dL) | 203 ± 31.7    | 204 ± 31.7    |
| HDL cholesterol (mg/dL)   | 44 ± 9.3      | 43 ± 9.3      |
| Triglycerides (mg/dL)     | 156 ± 45.7    | 155 ± 45.7    |
| LDL cholesterol (mg/dL)   | 103 ± 28.5    | 102 ± 28.5    |
| Systolic blood pressure (mmHg) | 127 ± 17.3  | 126 ± 17.3    |
| ACE inhibitors (yes = 1, no = 0) | 0.16 ± 0.03 | 0.16 ± 0.03   |

Data are mean ± SD. Baseline, after anesthetia induction; early CPB, 15 min after the initiation of CPB; late CPB, 15 min before separation from CPB; pre-CPB, immediately before CPB. *P < 0.05 vs. control.

Table 3—Multiple regression analysis to determine factors related to the insulin sensitivity at the end of CPB

| Independent variable      | β  | P value |
|---------------------------|----|---------|
| Age (y)                   | −0.01 | 0.93   |
| BM1 (kg/m²)               | −0.18 | 0.03   |
| HbA1c (%)                 | −0.08 | 0.15   |
| Fasting blood glucose (mmol/L) | −0.08   | 0.01   |
| HOMA-IR                   | −0.15 | 0.15   |
| Total cholesterol (mg/dL) | 0.03  | 0.36    |
| HDL cholesterol (mg/dL)   | 0.17  | 0.03    |
| Triglycerides (mg/dL)     | −0.27 | 0.01    |
| LDL cholesterol (mg/dL)   | −0.05 | 0.49    |
| Systolic blood pressure (mmHg) | 0.03     | 0.78  |
| ACE inhibitors (yes = 1, no = 0) | −0.06  | 0.56   |
| β-Blockers (yes = 1, no = 0) | −0.10  | 0.18   |
| Ca-channel blockers (yes = 1, no = 0) | 0.06  | 0.62   |
| Statins (yes = 1, no = 0) | −0.16 | 0.03   |
| Baseline of insulin sensitivity | 0.47  | <0.01  |
participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278
2. Pepine CJ. Optimizing lipid management in patients with acute coronary syndromes. Am J Cardiol 2003;91:30B–35B
3. Lazar HL. Should all patients receive statins before cardiac surgery: are more data necessary? J Thorac Cardiovasc Surg 2006;131:520–522
4. Eagle KA, Chopra V. Statins before coronary procedures: a new indication for an old friend. J Am Coll Cardiol 2010;56:111–112
5. Liakopoulos OJ, Choi YH, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J 2008;29:1548–1559
6. Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy: a meta-analysis of randomized trials. J Am Coll Cardiol 2010;56:1090–1109
7. Eagle KA, Guyton RA, Davidoff R, et al.; American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:e340–e437
8. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007;50:1707–1732
9. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–742
10. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98–107
11. Thongtang N, At M, Otorokazawa S, et al. Effects of maximal atorvastatin and rosuvasatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 2011;107:387–392
12. Anagnostis P, Athyros VG, Karagiannis A, Mikhailidis DP. Impact of statins on glucose metabolism—a matter of debate. Am J Cardiol 2011;107:1866
13. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycerone in hypercholesterolemic patients. J Am Coll Cardiol 2010;55:1209–1216
14. Schrickter T, Lattermann R, Schreiber M, Geisser W, Georgieff M, Radermacher P. The hyperglycaemic response to surgery: pathophysiology, clinical implications and modification by the anaesthetic technique. Clin Intensive Care 1999;9:118–128
15. Li E, Messina JL. Acute insulin resistance following injury. Trends Endocrinol Metab 2009;20:420–435
16. Sato H, Carvalho G, Sato T, Lattermann R, Matsukawa T, Schrickter T. The association of preoperative glycemic control, intraoperative insensitivity, and outcomes after cardiac surgery. J Clin Endocrinol Metab 2010;95:4338–4344
17. Ljungqvist O. Insulin resistance and outcomes in surgery. J Clin Endocrinol Metab 2010;95:4217–4219
18. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244–252
19. Ezekowitz IA, Straus SE, Majumdar SR, McAlister FA. Stroke: strategies for primary prevention. Am Fam Physician 2003;68:2373–2386
20. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691–696
21. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004;110(Suppl. 1):I145–I149
22. Fordermans D, Bax JJ, Kernai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003;107:1848–1851
23. Lindenauser PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291:2092–2099
24. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 2005;36:2072–2076
25. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924–1929
26. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207
27. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1–8
28. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205–1213
29. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetesologia 2006;49:1881–1892
30. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006;13:329–335
31. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. Curr Opin Clin Nutr Metab Care 1999;2:69–78
32. McAlister FA, Man J, Bistrizt L, Amad H, Tandon P. Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care 2003;26:1518–1524
33. Ouattara A, Lecomte P, Le Manaey Y, et al. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology 2005;103:687–694
34. Doemt C, Wijeysundera D, Karkouti K, et al. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2009;130:1144
35. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–1687
36. Kuhn EW, Liakopoulos OJ, Choi YH, Wahlers T. Current evidence for perioperative statins in cardiac surgery. Ann Thorac Surg 2011;92:372–379
37. Beattie WS, Wijeysundera DN. Statins and the “healthy user bias” in cardiac surgery. Anesth Analg 2010;111:261–263
38. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl- \textit{CoA} reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002;42:835–845
39. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003;26:1681–1684
40. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357–362

Sato and Associates